Loophole in Patent Law Brings ‘Miracle Drug’ to Patients Who Can’t Afford It

Live updates

1. 1h ago

   Bangladesh Patent Loophole Provides Low-Cost Cystic Fibrosis Drug

   Beximco Pharma is distributing TRIKO, a generic cystic fibrosis medication developed in Bangladesh. The drug reaches patients in six countries who cannot afford the original treatment. This effort leverages a patent law loophole to increase healthcare access.

   What's confirmed:

   • Beximco Pharma is supplying a low-cost generic cystic fibrosis drug called TRIKO.
   • The medication is distributed to patients across six countries.
   • The initiative uses a patent law loophole in Bangladesh.

   Still unconfirmed:

   • The original version of the drug costs $346,000 a year in the United States.
   confidence 90%
2. 4d ago

   Beximco Pharma Launches Low-Cost Cystic Fibrosis Drug TRIKO

   Beximco Pharma has begun supplying TRIKO, a low-cost generic version of a cystic fibrosis medication. The drug was developed in Bangladesh and is being distributed to patients across six countries. This initiative utilizes a patent law loophole to provide affordable treatment to patients who cannot afford the original medication.

   What's confirmed:

   • Beximco Pharma is supplying a low-cost generic cystic fibrosis medicine called TRIKO.
   • The generic medication was developed in Bangladesh.
   • Beximco Pharma has provided the affordable medicine to patients from six countries.

   Still unconfirmed:

   • Vertex Pharmaceuticals sells a year's supply of Trikafta for approximately $346,000 in the United States.
   • Trikafta has generated $49 billion in revenue since its 2019 launch.
   • Vertex Pharmaceuticals has blocked efforts to produce lower-cost generic versions of the drug.
   confidence 90%